A Novel Anti-Polysaccharide Antiserum for Detection of Clostridium Difficile Bacteria, and Diagnosis of Clostridium Difficile Colonization in Complex Clinical SpecimensTechnology #ua17-056
Questions about this technology? Ask a Technology Manager
- Gayatri Vedantam Associate professor, Animal and Comparative Biomedical Sciences
- Virinchipuram Viswanathan Associate Professor, SACBC
- Managed By
- Tod McCauley Sr. Licensing Manager (520) 626-7916
Title: A Novel Anti-Polysaccharide Antiserum for Detection of Clostridium difficile Bacteria, and Diagnosis of Clostridium difficile Colonization in Complex Clinical Specimens
Invention: The technology is an antiserum that is highly specific for Clostridium difficile. This target is available on all clinically relevant strains of Clostridium difficile bacteria.
Background: Clostridium difficile is a bacteria that causes serious intestinal issues. Each year there are approximately 500,000 cases of Clostridium difficile in the United States, which results in $4 billion in healthcare costs. The key to treating this infection and preventing recurrent infections is early, accurate diagnosis. Unfortunately, individuals with a low quantity of Clostridium difficile or non-toxic strains cannot be identified.
- Diagnostic assays
- Reduces repeat testing
- Highly specific to Clostridium difficile only